Retinoic Acid Receptor Alpha – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) – Pipeline Review, H1 2020’, provides in depth analysis on Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Oncology, Immunology, Ophthalmology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Male Health and Metabolic Disorders under development targeting Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

– The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects

– The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Io Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Orphanix GmbH

Ortho Dermatologics Inc

Polaryx Therapeutics Inc

Selphagy Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Avecho Biotechnology Ltd

Io Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Orphanix GmbH

Ortho Dermatologics Inc

Polaryx Therapeutics Inc

Selphagy Therapeutics Inc

Sol-Gel Technologies Ltd

Sunny BioDiscovery Inc

TherapyX Inc

Toko Pharmaceutical Industries Co Ltd

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(gemfibrozil + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IRX-5183 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OR-812 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBD-073 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize RAR Alpha and RXR Alpha for Acute Promyelocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RAR Alpha for Opthamology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones

Featured News & Press Releases

Jan 21, 2020: Sol-Gel announces presentation on Twyneo at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)

Jan 12, 2020: Syros announces new update on SY-1425

Jan 08, 2020: Sol-Gel hosts investor call to discuss positive results from Twyneo phase 3 program in Acne Vulgaris

Dec 30, 2019: Sol-Gel announces positive top-line phase 3 trial results of Twyneo for the treatment of acne vulgaris

Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris

Oct 24, 2019: Syros Announces new data from phase 2 trial of SY-1425 in combination with azacitidine demonstrating high response rates, rapid onset of action and favorable tolerability profile in RARA-Positive Newly Diagnosed Unfit AML Patients

Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference

Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference

Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form

Aug 01, 2019: Syros highlights key accomplishments and provides milestone update on SY-1425

Jul 09, 2019: GSK's Alitoc becoming salvation treatment for chronic hand eczema patients

Apr 15, 2019: Sol-Gel Technologies announces 50% enrollment in pivotal phase III TWIN Program for the treatment of Acne Vulgaris

Jan 06, 2019: Syros provides update on its acute myeloid leukemia drug candidate SY-1425

Dec 17, 2018: Sol-Gel Technologies initiates pivotal phase III clinical program of TWIN for the treatment of acne vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Advent Therapeutics Inc, H1 2020

Pipeline by Avecho Biotechnology Ltd, H1 2020

Pipeline by Io Therapeutics Inc, H1 2020

Pipeline by Novartis AG, H1 2020

Pipeline by Orphagen Pharmaceuticals Inc, H1 2020

Pipeline by Orphanix GmbH, H1 2020

Pipeline by Ortho Dermatologics Inc, H1 2020

Pipeline by Polaryx Therapeutics Inc, H1 2020

Pipeline by Selphagy Therapeutics Inc, H1 2020

Pipeline by Sol-Gel Technologies Ltd, H1 2020

Pipeline by Sunny BioDiscovery Inc, H1 2020

Pipeline by TherapyX Inc, H1 2020

Pipeline by Toko Pharmaceutical Industries Co Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports